MENY

Gällande vårdprogram

Fastställt av Regionala cancercentrum i samverkan 2018-12-11

25. Referenser

1.de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology. 2012;13(6):607-15.

2.Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J,  Ronco G, Segnan N, Suonio E, Törnberg S and von Karsa L  European guidelines for quality assurance in cervical cancer screening Second edition : supplements (2015) ISBN: 978-92-79-48538-1  DOI: 10.2875/859507.

3.Nicula FA, Anttila A, Neamtiu L, Zakelj MP, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. European journal of cancer. 2009;45(15):2679-84.

4.Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(4):553-60.

5.Cervixcancerprevention.  ARG-rapport nr 63, SFOG 2010.

6.http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer.

7.Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. British journal of cancer. 2014;111(5):965-9.

8.Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. Journal of the National Cancer Institute. 2008;100(9):622-9.

9.Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. Bmj. 2012;344:e900.

10.Darlin L, Borgfeldt C, Widen E, Kannisto P. Elderly women above screening age diagnosed with cervical cancer have a worse prognosis. Anticancer research. 2014;34(9):5147-51.

11.Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11(1):e1001585.

12.Wang ,J etal. Benefit of cervical screening at ages of 61-65 years in women with differing screening histories (2016, Submitted).

13.Strander B, Hallgren J, Sparen P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. Bmj. 2014;348:f7361.

14.Arbyn M, Rebolj M, De Kok IM, Fender M, Becker N, O'Reilly M, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. European journal of cancer. 2009;45(15):2671-8.

15.Vårdprogram. Gynekologisk cellprovskontroll i Västra Sjukvårdsregionen giltigt till 2016-08-31.

16.Sasieni P, Cuzick J. Routine audit is an ethical requirement of screening. Bmj. 2001;322(7295):1179.

17.Cuzick J. Routine audit of large-scale cervical cancer screening programs. Journal of the National Cancer Institute. 2008;100(9):605-6.

18.Lacour DE, Trimble C. Human papillomavirus in infants: transmission, prevalence, and persistence. Journal of pediatric and adolescent gynecology. 2012;25(2):93-7.

19.Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American journal of epidemiology. 2003;157(3):218-26.

20.Datautdrag från NKCx, implementering av primär HPV-screening i region Stockholm-Gotland.

21.Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. The New England journal of medicine. 1999;341(22):1633-8.

22.Sanner K, Wikstrom I, Gustavsson I, Wilander E, Lindberg JH, Gyllensten U, et al. Daily self-sampling for high-risk human papillomavirus (HR-HPV) testing. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015;73:1-7.

23.Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32.

24.Socialstyrelsen. Primärprevention  [cited 2015. Available from: http://socialstyrelsen.iterm.se/showterm.php?fTid=411.

25.Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. The New England journal of medicine. 2006;354(25):2645-54.

26.Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1-2):224-31.

27.Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:S1-15.

28.Simen-Kapeu A, La Ruche G, Kataja V, Yliskoski M, Bergeron C, Horo A, et al. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Cote d'Ivoire and Finland) with different tobacco exposure. Cancer Causes Control. 2009;20(2):163-70.

29.Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control. 2003;14(9):805-14.

30.Szarewski A, Jarvis MJ, Sasieni P, Anderson M, Edwards R, Steele SJ, et al. Effect of smoking cessation on cervical lesion size. Lancet. 1996;347(9006):941-3.

31.Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085-92.

32.IARC. Human Papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. 2012. https://lakemedelsverket.se/Alla-nyheter/NYHETER-2015/Inget-vetenskapligt-stod-for-att-HPV-vacciner-orsakar-CRPS-eller-POTS/.

33.Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5:F24-33.

34.Läkemedelsverket. http://www.lakemedelsverket.se/OVRIGA-SIDOR/HPV-vaccinering/ Acces data 2015-11-27 2012 [cited 2015 27 November 2015].

35.Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England journal of medicine. 2015;372(8):711-23.

36.Dillner J, Brown DR. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? Expert Rev Mol Med. 2004;6(9):1-21.

37.FASS. Cervarix 2015.

38.FASS. Gardasil 2015 [Available from: http://www.fass.se/LIF/product?4&userType=0&nplId=20051216000104&docType=6.

39.Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013;10(7):400-10.

40.Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Jama. 2014;311(6):597-603.

41.Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. Journal of the National Cancer Institute. 2013;105(7):469-74.

42.Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. Bmj. 2014;348:g1458.

43.Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf. 2015;14(5):697-712.

44.https://lakemedelsverket.se/Alla-nyheter/NYHETER-2015/Inget-vetenskapligt-stod-for-att-HPV-vacciner-orsakar-CRPS-eller-POTS/.

45.Socialstyrelsen SOSFS 2008:31. Ändring I föreskrifterna (SOSFS 2006:22) om vaccination av barn. Socialstyrelsen, Stockholm, 2008.

46.Smittskyddsinstitutet. Övervakning av HPV-vaccination i Sverige. Arbetsplan. Smittskyddsinstitutet, Solna, 2012.

47.Svensk författningssamling SFS 2012:453. Lag om register över nationella vaccinationsprogram.

48.Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. Bmj. 2013;347:f5906.

49.Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. Jama. 2015;313(1):54-61.

50. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/11/news_detail_002436.jsp&mid=WC0b01ac058004d5c1 . Accessed 20160317.

51.http://www.folkhalsomyndigheten.se/amnesomraden/statistik-och-undersokningar/vaccinationsstatistik/statistik-for-hpv-vaccinationer/ . Accessed 20160124.

52.Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study. PLoS One. 2015 Jul 28;10(7):e0134185.

53.Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. The Journal of infectious diseases. 2012;206(6):860-6.

54.Herweijer E, Sundstrom K, Ploner A, Uhnoo I, Sparen P, Arnheim-Dahlstrom L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. International journal of cancer Journal international du cancer. 2016.

55.SOSFS 20013:13. http://www.socialstyrelsen.se/sosfs/2003-13.

56.http://www.cancercentrum.se/samverkan/om-oss/nyheter/ny-kallelse-okar-deltagandet-i-screening/.

57.Segnan N, Senore C, Giordano L, Ponti A, Ronco G. Promoting participation in a population screening program for breast and cervical cancer: a randomized trial of different invitation strategies. Tumori. 1998;84(3):348-53.

58.http://cancercentrum.se/globalassets/vara-uppdrag/prevention-tidig-upptackt/gynekologisk-cellprovskontroll/vast/kvalitetsregister/kvalitetsrapporter/arsrapport2014.pdf.

59.Svenskarna och Internet 2015 http://www.soi2015.se/fakta-information-och-e-handel/e-legitimation-mobilt-bankid-och-swish/.

60.Screening för livmoderhalscancer med HPV test. En systematisk litteraturöversikt, Socialstyrelsen och SBU; 2014.

61.Screening för livmoderhalscancer. Rekommendation och bedömningsunderlag. Stockholm: Socialstyrelsen; 2015. Artikelnr 2015-6-39.

62.Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. British medical journal. 1986;293(6548):659-64.

63.Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88(10):2283-9.

64.Lindqvist PG, Hellsten C, Rippe A. Screening history of women in Malmo with invasive cervical cancer. European journal of obstetrics, gynecology, and reproductive biology. 2008;137(1):77-83.

65.Azerkan F, Sparen P, Sandin S, Tillgren P, Faxelid E, Zendehdel K. Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. International journal of cancer Journal international du cancer. 2012;130(4):937-47.

66.International Code of Ethic for Midwives (2008).  

67.Foster P, Anderson CM. Reaching targets in the national cervical screening programme: are current practices unethical? Journal of medical ethics. 1998;24(3):151-7.

68.Waller J, Bartoszek M, Marlow L, Wardle J. Barriers to cervical cancer screening attendance in England: a population-based survey. Journal of medical screening. 2009;16(4):199-204.

69.Oscarsson MG, Benzein EG, Wijma BE. Reasons for non-attendance at cervical screening as reported by non-attendees in Sweden. Journal of psychosomatic obstetrics and gynaecology. 2008;29(1):23-31.

70.Eaker S, Adami HO, Sparen P. Reasons women do not attend screening for cervical cancer: a population-based study in Sweden. Prev Med. 2001;32(6):482-91.

71.Soneji S, Fukui N. Socioeconomic determinants of cervical cancer screening in Latin America. Revista panamericana de salud publica = Pan American journal of public health. 2013;33(3):174-82.

72.Mandelblatt J, Traxler M, Lakin P, Thomas L, Chauhan P, Matseoane S, et al. A nurse practitioner intervention to increase breast and cervical cancer screening for poor, elderly black women. The Harlem Study Team. Journal of general internal medicine. 1993;8(4):173-8.

73.Morrell S, Taylor R, Zeckendorf S, Niciak A, Wain G, Ross J. How much does a reminder letter increase cervical screening among under-screened women in NSW? Australian and New Zealand journal of public health. 2005;29(1):78-84.

74.Eaker S, Adami HO, Granath F, Wilander E, Sparen P. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004;13(3):346-54.

75. Sammanställning av Kvalitetsdata 2014 gällande Cervixcancerprevention i Västra sjukvårdsregionen. Göteborg: Regionalt Cancercentrum väst, 2015

76.Broberg G, Jonasson JM, Ellis J, Gyrd-Hansen D, Anjemark B, Glantz A, et al. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial. International journal of cancer Journal international du cancer. 2013;133(1):164-71.

77.Broberg G, Gyrd-Hansen D, Miao Jonasson J, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. International journal of cancer Journal international du cancer. 2014;134(9):2223-30.

78.Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. Bmj. 2010;340:c1040.

79.Virtanen A, Anttila A, Luostarinen T, Nieminen P. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. International journal of cancer Journal international du cancer. 2011;128(11):2681-7.

80.Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. British journal of cancer. 2011;104(6):915-20.

81.Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. International journal of cancer Journal international du cancer. 2007;120(7):1505-10.

82.Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. British journal of cancer. 2009;101(5):871-4.

83.Wikstrom I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. British journal of cancer. 2011;105(3):337-9.

84.Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. International journal of cancer Journal international du cancer. 2012;130(5):1128-35.

85.Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. European journal of cancer. 2015;51(16):2375-85.

86.Rodvall Y, Kemetli L, Tishelman C, Tornberg S. Factors related to participation in a cervical cancer screening programme in urban Sweden. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation. 2005;14(5):459-66.

87.Olsson E, Lau M, Lifvergren S, Chakhunashvili A. Community collaboration to increase foreign-born women's participation in a cervical cancer screening program in Sweden: a quality improvement project. International journal for equity in health. 2014;13:62.

88.Arbyn M,  Flemish Working Party Sampling. A technical guideline: collection of adequate Pap smears of the uterine cervix. IPH/EPI-REPORTS 4, 1-53. 2000. Brussels, Scientific Institute of Public Health. 

89.Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, McGoogan E, Patnick J, Bergeron C, Baldauf JJ et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18: 133-9.

90.Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International journal of cancer Journal international du cancer. 2009;124(3):516-20.

91.http://www.socialstyrelsen.se/riktlinjer/nationellascreeningprogram/livmoderhalscancer-screeningme.

92.Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. The New England journal of medicine. 2009;360(14):1385-94.

93.Arbyn, M., P.J. Snijders, C.J. Meijer, J. Berkhof, K. Cuschieri, B.J. Kocjan, and M. Poljak. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect, 2015. 21(9): p. 817-26.

94.www.equalis.se; www.hpvcenter.se; www.ukneqas.org.uk; www.qcmd.org; .

95.Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. Journal of clinical microbiology. 2014;52(2):449-59.

96.https://www.cancercentrum.se/globalassets/vara-uppdrag/prevention-tidig-upptackt/gynekologisk-cellprovskontroll/nationellt-kvalitetsregister/historik-och-innehall/hpv-specifikation-v9-2015-06-16.pdf.

97.Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecologic oncology. 2015;136(2):189-97.

98.Huh WK, Williams E, Huang J, Bramley T, Poulios N. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Applied health economics and health policy. 2015;13(1):95-107.

99.Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011;20(7):1398-409.

100.Smelov V, Elfstrom KM, Johansson AL, Eklund C, Naucler P, Arnheim-Dahlstrom L, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. International journal of cancer Journal international du cancer. 2015;136(5):1171-80.

101.Dahlstrom LA, Ylitalo N, Sundstrom K, Palmgren J, Ploner A, Eloranta S, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. International journal of cancer Journal international du cancer. 2010;127(8):1923-30.

102.Nayar R,Wilbur DC, eds. The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria, and Explanatory Notes. 3rd ed. Springer; 2015.

103. Arbyn M, Anttila A, Jordan J, et al., editors. European Commission. In. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd edition. Luxembourg: Office for Official Publications of the European Communities; 2008. pp. 1–291. http://www.cervicalcheck.ie/_fileupload/Downloads/IARC%20QA%20guidelines%20(2008).pdf.

104.Uijterwaal MH, Witte BI, Van Kemenade FJ, Rijkaart D, Ridder R, Berkhof J, et al. Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. British journal of cancer. 2014;110(6):1579-86.

105.Shidham VB, Mehrotra R, Varsegi G, D'Amore KL, Hunt B, Narayan R. p16 immunocytochemistry on cell blocks as an adjunct to cervical cytology: Potential reflex testing on specially prepared cell blocks from residual liquid-based cytology specimens. Cytojournal. 2011;8:1.

106.Bilaga till Nationellt vårdprogram för cervixcancer http://www.cancercentrum.se/samverkan/cancerdiagnoser/gynekologi/livmoderhals-vagina/.

107.Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Journal of lower genital tract disease. 2012;16(3):205-42.

108.Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. Jama. 2002;287(16):2140-1.

109.Kolstad P, Klem V. Long-term followup of 1121 cases of carcinoma in situ. Obstetrics and gynecology. 1976;48(2):125-9.

110.Kurman RJ, Carcangui ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of th Female Reproductive Organs. Lyon: IARC; 2014. 

111.Galgano MT, Castle PE, Stoler MH, Solomon D, Schiffman M. Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? American journal of clinical pathology. 2008;130(1):65-70.

112.Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, et al. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. International journal of cancer Journal international du cancer. 2011;128(6):1354-62.

113.Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. The Journal of infectious diseases. 2012;205(10):1544-53.

114.Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstetrics and gynecology. 2010;116(6):1373-80.

115.Mills AM, Paquette C, Castle PE, Stoler MH. Risk stratification by p16 immunostaining of CIN1 biopsies: a retrospective study of patients from the quadrivalent HPV vaccine trials. The American journal of surgical pathology. 2015;39(5):611-7.

116.Sundström K, Lu D, Elfström KM, Wang J, Andrae B, Dillner J, and Sparén P Follow-up of women with low grade cervical cytological abnormalities: a nationwide cohort study. Submitted.

117.Wang J, Andrae B, Sundstrom K, Strom P, Ploner A, Elfstrom KM, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. Bmj. 2016;352:i276.

118.Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. Journal of the National Cancer Institute. 2009;101(2):88-99.

119.Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. American journal of obstetrics and gynecology. 2005;193(3 Pt 1):650-7.

120.Bjerre P, Silfverdal L, Dillner L, Hagmar B, Edvardsson H, Dillner J, et al. A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. American journal of obstetrics and gynecology. 2008;199(1):24 e1-7.

121.Yang B, Pretorius RG, Belinson JL, Zhang X, Burchette R, Qiao YL. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3. Gynecologic oncology. 2008;110(1):32-6.

122.Bornstein J, Bentley J, Bosze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstetrics and gynecology. 2012;120(1):166-72.

123.Strander B, Ellstrom-Andersson A, Franzen S, Milsom I, Radberg T. The performance of a new scoring system for colposcopy in detecting high-grade dysplasia in the uterine cervix. Acta obstetricia et gynecologica Scandinavica. 2005;84(10):1013-7.

124.Bowring J, Strander B, Young M, Evans H, Walker P. The Swede score: evaluation of a scoring system designed to improve the predictive value of colposcopy. Journal of lower genital tract disease. 2010;14(4):301-5.

125.Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstetrics and gynecology. 2006;108(2):264-72.

126.Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33(1):83-9.

127.Mogensen ST, Bak M, Dueholm M, Frost L, Knoblauch NO, Praest J, et al. Cytobrush and endocervical curettage in the diagnosis of dysplasia and malignancy of the uterine cervix. Acta obstetricia et gynecologica Scandinavica. 1997;76(1):69-73.

128.Boardman LA, Meinz H, Steinhoff MM, Heber WW, Blume J. A randomized trial of the sleeved cytobrush and the endocervical curette. Obstetrics and gynecology. 2003;101(3):426-30.

129.Goksedef BP, Akbayir O, Numanoglu C, Corbacioglu A, Guraslan H, Bakir LV, et al. Evaluation of endocervical canal in women with minimal cervical cytological abnormalities. Journal of lower genital tract disease. 2013;17(3):261-6.

130.Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstetrics and gynecology. 1998;92(4 Pt 2):727-35.

131.Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. Journal of the National Cancer Institute. 2003;95(17):1336-43.

132.Pretorius RG, Belinson JL, Azizi F, Peterson PC, Belinson S. Utility of random cervical biopsy and endocervical curettage in a low-risk population. Journal of lower genital tract disease. 2012;16(4):333-8.

133.Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. American journal of obstetrics and gynecology. 2004;191(2):430-4.

134.Cruickshank ME, Cotton SC, Sharp L, Smart L, Walker LG, Little J, et al. Management of women with low grade cytology: how reassuring is a normal colposcopy examination? BJOG : an international journal of obstetrics and gynaecology. 2015;122(3):380-6.

135.Kelly RS, Walker P, Kitchener H, Moss SM. Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. BJOG : an international journal of obstetrics and gynaecology. 2012;119(1):20-5.

136.Smith MC, Keech SE, Perryman K, Soutter WP. A long-term study of women with normal colposcopy after referral with low-grade cytological abnormalities. BJOG : an international journal of obstetrics and gynaecology. 2006;113(11):1321-8.

137.Elfgren, K  Elfström KM, Naucler P, Arnheim-DahlströmL,  DillnerJ Management of women with Human Papillomavirus (HPV) persistence detected in organized HPV screening: Long-term follow-up of randomised clinical trial. Submitted for publication.

138.Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Bmj. 2009;339:b2569.

139.Elfström MK, Dillner J opublicerade data Pers. medd. 2016.

140.Verdoodt F, Jiang X, Williams M, Schnatz PF, Arbyn M. High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. International journal of cancer Journal international du cancer. 2016;138(2):303-10.

141.Nygard JF, Sauer T, Nygard M, Skare GB, Thoresen SO. CIN 2/3 and cervical cancer in an organised screening programme after an unsatisfactory or a normal Pap smear: a seven-year prospective study of the Norwegian population-based screening programme. Journal of medical screening. 2004;11(2):70-6.

142.Silfverdal L, Kemetli L, Sparen P, Andrae B, Strander B, Ryd W, et al. Risk of invasive cervical cancer in relation to clinical investigation and treatment after abnormal cytology: a population-based case-control study. International journal of cancer Journal international du cancer. 2011;129(6):1450-8.

143.Massad LS, Tate N, Cejtin E, Collins YC. Quantifying the risk of cervical intraepithelial neoplasia in women with unsatisfactory colposcopy results. Journal of lower genital tract disease. 2005;9(1):23-8.

144.Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatisfactory colposcopy and the use of vaginal estrogen cream: an observational study of clinical outcomes for women in low estrogen states. J Obstet Gynaecol Res. 2015;41(3):440-4.

145.Piccoli R, Mandato VD, Lavitola G, Acunzo G, Bifulco G, Tommaselli GA, et al. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: implications for management. European journal of obstetrics, gynecology, and reproductive biology. 2008;140(2):269-74.

146.Makkar B, Batra S, Gandhi G, Zutshi V, Goswami D. Vaginal misoprostol versus vaginal estradiol in overcoming unsatisfactory colposcopy. Gynecologic and obstetric investigation. 2014;77(3):176-9.

147.Saunders N, Anderson D, Gilbert L, Sharp F. Unsatisfactory colposcopy and the response to orally administered oestrogen: a randomized double blind placebo controlled trial. Br J Obstet Gynaecol. 1990;97(8):731-3.

148.Aggarwal R, Suneja A, Agarwal N, Mishra K. Role of misoprostol in overcoming an unsatisfactory colposcopy: a randomized double-blind placebo-controlled clinical trial. Gynecologic and obstetric investigation. 2006;62(2):115-20.

149.Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 1993;12(2):186-92.

150.Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. International journal of cancer Journal international du cancer. 2013;132(4):854-67.

151.Sasieni P, Castanon A, Landy R, Kyrgiou M, Kitchener H, Quigley M, et al. Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium. BJOG : an international journal of obstetrics and gynaecology. 2015.

152.Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. Bmj. 2014;349:g6192.

153.Bevis KS, Biggio JR. Cervical conization and the risk of preterm delivery. American journal of obstetrics and gynecology. 2011;205(1):19-27.

154.Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. International journal of cancer Journal international du cancer. 2014;135(2):453-66.

155.Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al. Tobacco smoking and regression of low-grade cervical abnormalities. Cancer science. 2010;101(9):2065-73.

156.Conner SN, Frey HA, Cahill AG, Macones GA, Colditz GA, Tuuli MG. Loop electrosurgical excision procedure and risk of preterm birth: a systematic review and meta-analysis. Obstetrics and gynecology. 2014;123(4):752-61.

157.Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK. Depth of cervical cone removed by loop electrosurgical excision procedure and subsequent risk of spontaneous preterm delivery. Obstetrics and gynecology. 2009;114(6):1232-8.

158.Heinonen A, Gissler M, Riska A, Paavonen J, Tapper AM, Jakobsson M. Loop electrosurgical excision procedure and the risk for preterm delivery. Obstetrics and gynecology. 2013;121(5):1063-8.

159.Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-98.

160.Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Archives of gynecology and obstetrics. 2014;289(1):85-99.

161.Kietpeerakool C, Srisomboon J, Khobjai A, Chandacham A, Tucksinsook U. Complications of loop electrosurgical excision procedure for cervical neoplasia: a prospective study. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2006;89(5):583-7.

162.Sutthichon P, Kietpeerakool C. Perioperative complications of an outpatient loop electrosurgical excision procedure: a review of 857 consecutive cases. Asian Pacific journal of cancer prevention : APJCP. 2009;10(3):351-4.

163.Petry KU. Management options for cervical intraepithelial neoplasia. Best practice & research Clinical obstetrics & gynaecology. 2011;25(5):641-51.

164.Gurumurthy M, Cotton SC, Sharp L, Smart L, Little J, Waugh N, et al. Postcolposcopy management of women with histologically proven CIN 1: results from TOMBOLA. Journal of lower genital tract disease. 2014;18(3):203-9.

165.Bansal N, Wright JD, Cohen CJ, Herzog TJ. Natural history of established low grade cervical intraepithelial (CIN 1) lesions. Anticancer research. 2008;28(3B):1763-6.

166.McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. The Lancet Oncology. 2008;9(5):425-34.

167.Wilkinson TM, Sykes PH, Simcock B, Petrich S. Recurrence of high-grade cervical abnormalities following conservative management of cervical intraepithelial neoplasia grade 2. American journal of obstetrics and gynecology. 2015;212(6):769 e1-7.

168.Guedes AC, Zeferino LC, Syrjanen KJ, Brenna SM. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer research. 2010;30(6):2319-23.

169.Preaubert L, Gondry J, Mancini J, Chevreau J, Lamblin G, Atallah A, et al. Benefits of Direct Colposcopic Vision for Optimal LLETZ Procedure: A Prospective Multicenter Study. Journal of lower genital tract disease. 2016;20(1):15-21.

170.Anderson MC, Hartley RB. Cervical crypt involvement by intraepithelial neoplasia. Obstetrics and gynecology. 1980;55(5):546-50.

171.Boonstra H, Aalders JG, Koudstaal J, Oosterhuis JW, Janssens J. Minimum extension and appropriate topographic position of tissue destruction for treatment of cervical intraepithelial neoplasia. Obstetrics and gynecology. 1990;75(2):227-31.

172.Ghaem-Maghami S, De-Silva D, Tipples M, Lam S, Perryman K, Soutter W. Determinants of success in treating cervical intraepithelial neoplasia. BJOG : an international journal of obstetrics and gynaecology. 2011;118(6):679-84.

173.Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. The Lancet Oncology. 2007;8(11):985-93.

174.Flannelly G, Bolger B, Fawzi H, De Lopes AB, Monaghan JM. Follow up after LLETZ: could schedules be modified according to risk of recurrence? BJOG : an international journal of obstetrics and gynaecology. 2001;108(10):1025-30.

175.Baalbergen A, Helmerhorst TJ. Adenocarcinoma in situ of the uterine cervix--a systematic review. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(9):1543-8.

176.Baalbergen A, Molijn AC, Quint WG, Smedts F, Helmerhorst TJ. Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri. Journal of lower genital tract disease. 2015;19(3):239-43.

177.Munro A, Leung Y, Spilsbury K, Stewart CJ, Semmens J, Codde J, et al. Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? Gynecologic oncology. 2015;137(2):258-63.

178.Tierney KE, Lin PS, Amezcua C, Matsuo K, Ye W, Felix JC, et al. Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. American journal of obstetrics and gynecology. 2014;210(4):366 e1-5.

179.Costa S, Venturoli S, Negri G, Sideri M, Preti M, Pesaresi M, et al. Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. Gynecologic oncology. 2012;124(3):490-5.

180.Martin-Hirsch PP, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2013;12:CD001421.

181.Lipscomb GH, Roberts KA, Givens VM, Robbins D. A trial that compares Monsel's paste with ball electrode for hemostasis after loop electrosurgical excision procedure. American journal of obstetrics and gynecology. 2006;194(6):1591-4; discussion 5.

182.Penna C, Fambrini M, Fallani MG, Pieralli A, Scarselli G, Marchionni M. Laser CO2 conization in postmenopausal age: risk of cervical stenosis and unsatisfactory follow-up. Gynecologic oncology. 2005;96(3):771-5.

183.Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG : an international journal of obstetrics and gynaecology. 2012;119(6):685-91.

184.Soutter WP, Butler JS, Tipples M. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. BJOG : an international journal of obstetrics and gynaecology. 2006;113(5):511-4.

185.Strander B, Ryd W, Wallin KL, Warleby B, Zheng B, Milsom I, et al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? European journal of cancer. 2007;43(12):1849-55.

186.Asciutto KC HE, Darlin L, Forslund O, Borgfeldt C. Follow-up with HPV test and cytology as test of cure at six months after conisation is reliable. [Epub ahead of print] Acta obstetricia et gynecologica Scandinavica. 2016.

187.Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. The Lancet Oncology. 2011;12(5):441-50.

188.Uijterwaal MH, Kocken M, Berkhof J, Bekkers RL, Verheijen RH, Helmerhorst TJ, et al. Posttreatment assessment of women at risk of developing high-grade cervical disease: proposal for new guidelines based on data from the Netherlands. Journal of lower genital tract disease. 2014;18(4):338-43.

189.Cubie HA, Canham M, Moore C, Pedraza J, Graham C, Cuschieri K. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). Journal of clinical pathology. 2014;67(6):458-63.

190.Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecologic oncology. 2000;79(2):294-9.

191.Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecologic oncology. 1997;66(1):108-13.

192.Cruickshank ME, Sharp L, Chambers G, Smart L, Murray G. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. BJOG : an international journal of obstetrics and gynaecology. 2002;109(5):579-81.

193.Legood R, Smith M, Lew JB, Walker R, Moss S, Kitchener H, et al. Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. Bmj. 2012;345:e7086.

194.Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstetrics and gynecology. 2002;100(5 Pt 1):965-71.

195.Rositch AF, Soeters HM, Offutt-Powell TN, Wheeler BS, Taylor SM, Smith JS. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecologic oncology. 2014;132(3):767-79.

196.Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358(9295):1782-3.

197.Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecologic oncology. 2003;90(2):358-65.

198.Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. The Lancet Oncology. 2011;12(7):663-72.

199.Wright TC, Jr., Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. American journal of obstetrics and gynecology. 2012;206(1):46 e1- e11.

200.Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. Journal of the National Cancer Institute. 2011;103(18):1387-96.

201.Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstetrics and gynecology. 2008;111(4):847-56.

202.Castle PE, Fetterman B, Thomas Cox J, Shaber R, Poitras N, Lorey T, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstetrics and gynecology. 2010;116(1):76-84.

203.Barron S, Austin RM, Li Z, Zhao C. Follow-up outcomes in a large cohort of patients with HPV-negative LSIL cervical screening test results. American journal of clinical pathology. 2015;143(4):485-91.

204.Gosvig CF, Huusom LD, Andersen KK, Duun-Henriksen AK, Frederiksen K, Iftner A, et al. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. International journal of cancer Journal international du cancer. 2015;137(12):2927-33.

205.Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015.

206.Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. Journal of lower genital tract disease. 2013;17(5 Suppl 1):S78-84.

207.Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. International journal of cancer Journal international du cancer. 2006;118(8):2048-55.

208.Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. Bmj. 2007;335(7629):1077.

209.Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. American journal of obstetrics and gynecology. 2008;199(1):3-9.

210.Origoni M, Salvatore S, Perino A, Cucinella G, Candiani M. Cervical Intraepithelial Neoplasia (CIN) in pregnancy: the state of the art. European review for medical and pharmacological sciences. 2014;18(6):851-60.

211.Norstrom A, Jansson I, Andersson H. Carcinoma of the uterine cervix in pregnancy. A study of the incidence and treatment in the western region of Sweden 1973 to 1992. Acta obstetricia et gynecologica Scandinavica. 1997;76(6):583-9.

212.Karrberg C, Radberg T, Holmberg E, Norstrom A. Support for down-staging of pregnancy-associated cervical cancer. Acta obstetricia et gynecologica Scandinavica. 2015;94(6):654-9.

213.Fader AN, Alward EK, Niederhauser A, Chirico C, Lesnock JL, Zwiesler DJ, et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation. American journal of obstetrics and gynecology. 2010;203(2):113 e1-6.

214.Robinson WR, Webb S, Tirpack J, Degefu S, O'Quinn AG. Management of cervical intraepithelial neoplasia during pregnancy with LOOP excision. Gynecologic oncology. 1997;64(1):153-5.

215.Danhof NA, Kamphuis EI, Limpens J, van Lonkhuijzen LR, Pajkrt E, Mol BW. The risk of preterm birth of treated versus untreated cervical intraepithelial neoplasia (CIN): a systematic review and meta-analysis. European journal of obstetrics, gynecology, and reproductive biology. 2015;188:24-33.

216.Singer AM, J. . Lower Genital Tract Precancer Colposcopy, Pathology and Treatment. 2nd Edition. Oxford: Black Science; 2000.

217.Campion MJ, Sedlacek TV. Colposcopy in pregnancy. Obstetrics and gynecology clinics of North America. 1993;20(1):153-63.

218.Baldauf JJ, Dreyfus M, Ritter J, Philippe E. Colposcopy and directed biopsy reliability during pregnancy: a cohort study. European journal of obstetrics, gynecology, and reproductive biology. 1995;62(1):31-6.

219.Woodrow N, Permezel M, Butterfield L, Rome R, Tan J, Quinn M. Abnormal cervical cytology in pregnancy: experience of 811 cases. The Australian & New Zealand journal of obstetrics & gynaecology. 1998;38(2):161-5.

220.Paraskevaidis E, Koliopoulos G, Kalantaridou S, Pappa L, Navrozoglou I, Zikopoulos K, et al. Management and evolution of cervical intraepithelial neoplasia during pregnancy and postpartum. European journal of obstetrics, gynecology, and reproductive biology. 2002;104(1):67-9.

221.Karrberg C, Brannstrom M, Strander B, Ladfors L, Radberg T. Colposcopically directed cervical biopsy during pregnancy; minor surgical and obstetrical complications and high rates of persistence and regression. Acta obstetricia et gynecologica Scandinavica. 2013;92(6):692-9.

222.Karrberg C, Ryd W, Strander B, Brannstrom M, Radberg T. Histological diagnosis and evaluation of the Swede score colposcopic system in a large cohort of pregnant women with atypical cervical cytology or cervical malignancy signs. Acta obstetricia et gynecologica Scandinavica. 2012;91(8):952-8.

223.Hannigan EV, Whitehouse HH, 3rd, Atkinson WD, Becker SN. Cone biopsy during pregnancy. Obstetrics and gynecology. 1982;60(4):450-5.

224.Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstetrics and gynecology. 1999;93(3):359-62.

225.Palle C, Bangsboll S, Andreasson B. Cervical intraepithelial neoplasia in pregnancy. Acta obstetricia et gynecologica Scandinavica. 2000;79(4):306-10.

226.Slama J, Freitag P, Dundr P, Duskova J, Fischerova D, Zikan M, et al. Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. Cytopathology : official journal of the British Society for Clinical Cytology. 2012;23(6):383-8.

227.Tam KF, Cheung AN, Szeto E, Ngan HY. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. European journal of obstetrics, gynecology, and reproductive biology. 2011;155(2):213-6.

228.Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS. 2012;26(17):2211-22.

229.Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003(31):41-6.

230.Denslow SA, Rositch AF, Firnhaber C, Ting J, Smith JS. Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS. 2014;25(3):163-77.

231.Carlander C, Wagner P, Svedhem V, Elfgren K, Westling K, Sönnerborg A, Sparén P. Impact of immunosuppression and region of birth on risk of cervical neoplasia among HIV-infected migrants in Sweden Submitted to International Journal of Cancer, IJC.

232.Brickman C, Palefsky JM. Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era. Curr HIV/AIDS Rep. 2015;12(4):388-96.

233.Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. The Lancet Oncology. 2009;10(12):1152-9.

234.Maranga IO, Hampson L, Oliver AW, He X, Gichangi P, Rana F, et al. HIV Infection Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women. Open Virol J. 2013;7:19-27.

235.McDonald AC, Tergas AI, Kuhn L, Denny L, Wright TC, Jr. Distribution of Human Papillomavirus Genotypes among HIV-Positive and HIV-Negative Women in Cape Town, South Africa. Front Oncol. 2014;4:48.

236.Heard I, Cubie HA, Mesher D, Sasieni P, Group M-S. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG : an international journal of obstetrics and gynaecology. 2013;120(1):41-9.

237.Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. The Journal of infectious diseases. 2010;201(5):681-90.

238.Firnhaber C, Westreich D, Schulze D, Williams S, Siminya M, Michelow P, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc. 2012;15(2):17382.

239.Zeier MD, Botha MH, van der Merwe FH, Eshun-Wilson I, van Schalkwyk M, la Grange M, et al. Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus. Journal of lower genital tract disease. 2012;16(3):243-50.

240.Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002;16(13):1799-802.

241.Nguyen ML, Flowers L. Cervical cancer screening in immunocompromised women. Obstetrics and gynecology clinics of North America. 2013;40(2):339-57.

242.Massad LS, Xie X, D'Souza G, Darragh TM, Minkoff H, Wright R, et al. Incidence of cervical precancers among HIV-seropositive women. American journal of obstetrics and gynecology. 2015;212(5):606 e1-8.

243.Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. Jama. 2012;308(4):362-9.

244.Davies O, Rajamanoharan S, Balachandran T. Cervical screening in HIV-positive women in the East of England: recent CD4 as the predictive risk factor. Int J STD AIDS. 2015;26(13):945-50.

245.Thorsteinsson K, Ladelund S, Jensen-Fangel S, Katzenstein TL, Johansen IS, Pedersen G, et al. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population. HIV Med. 2016;17(1):7-17.

246.Thorsteinsson K, Ladelund S, Jensen-Fangel S, Katzenstein TL, Johansen IS, Pedersen G, et al. Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population. BMC Infect Dis. 2014;14:256.

247.Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, et al. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15 Suppl 2:1-92.

248.Stewart Massad L, D'Souza G, Darragh TM, Minkoff H, Wright R, Kassaye S, et al. Accuracy of colposcopy in HIV seropositive and seronegative women with abnormal Pap tests. Gynecologic oncology. 2014;135(3):481-6.

249.Massad LS, Evans CT, Strickler HD, Burk RD, Watts DH, Cashin L, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstetrics and gynecology. 2005;106(3):525-32.

250.Adam Y, van Gelderen CJ, de Bruyn G, McIntyre JA, Turton DA, Martinson NA. Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population. BMC Cancer. 2008;8:211.

251.Lehtovirta P, Paavonen J, Heikinheimo O. Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS. 2008;19(1):37-41.

252.Massad LS, Evans CT, Minkoff H, Watts DH, Strickler HD, Darragh T, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstetrics and gynecology. 2004;104(5 Pt 1):1077-85.

253.Gonzalez P, Hildesheim A, Rodriguez AC, Schiffman M, Porras C, Wacholder S, et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(12):3044-54.

254.Brannstrom J, Svedhem Johansson V, Marrone G, Wendahl S, Yilmaz A, Blaxhult A, et al. Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden. HIV Med. 2015.

255.Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.

256.Paternoster DM, Cester M, Resente C, Pascoli I, Nanhorngue K, Marchini F, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc. 2008;40(6):1877-80.

257.Marschalek J, Helmy S, Schmidt A, Polterauer S, Sobulska M, Gyoeri GP, et al. Prevalence of genital dysplasia after kidney transplantation--a retrospective, non-interventional study from two centers. Acta obstetricia et gynecologica Scandinavica. 2015;94(8):891-7.

258.Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the United States. Am J Transplant. 2013;13(12):3202-9.

259.Tanaka Y, Ueda Y, Kakuda M, Kubota S, Matsuzaki S, Nakagawa S, et al. Clinical outcomes of abnormal cervical cytology and human papillomavirus-related lesions in patients with organ transplantation: 11-year experience at a single institution. Int J Clin Oncol. 2015.

260.Wang Y, Brinch L, Jebsen P, Tanbo T, Kirschner R. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):747-53.

261.Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-83.

262.Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464-71.

263.Wadstrom H, Frisell T, Sparen P, Askling J, group As. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Ann Rheum Dis. 2016.

264.Kim SC, Glynn RJ, Giovannucci E, Hernandez-Diaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74(7):1360-7.

265.Zard E, Arnaud L, Mathian A, Chakhtoura Z, Hie M, Touraine P, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730-5.

266.Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sorensen HT, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12(2):265-73 e1.

267.Rungoe C, Simonsen J, Riis L, Frisch M, Langholz E, Jess T. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13(4):693-700 e1.

268.Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015;21(5):1089-97.

269.Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 7:H1-31.

270.Forss A, Tishelman C, Widmark C, Lundgren E, Sachs L, Tornberg S. 'I got a letter...' a qualitative study of women's reasoning about attendance in a cervical cancer screening programme in urban Sweden. Psycho-oncology. 2001;10(1):76-87.

271.Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, et al. The psychosocial impact of an abnormal cervical smear result. Psycho-oncology. 2012;21(10):1071-81.

272.Korfage IJ, van Ballegooijen M, Huveneers H, Essink-Bot ML. Anxiety and borderline PAP smear results. European journal of cancer. 2010;46(1):134-41.

273.O'Connor M, Gallagher P, Waller J, Martin CM, O'Leary JJ, Sharp L, et al. Adverse psychological outcomes following colposcopy and related procedures: a systematic review. BJOG : an international journal of obstetrics and gynaecology. 2015.

274.O'Connor M, Costello L, Murphy J, Prendiville W, Martin CM, O'Leary JJ, et al. 'I don't care whether it's HPV or ABC, I just want to know if I have cancer.' Factors influencing women's emotional responses to undergoing human papillomavirus testing in routine management in cervical screening: a qualitative study. BJOG : an international journal of obstetrics and gynaecology. 2014;121(11):1421-9.

275.Sharp L, Cotton S, Carsin AE, Gray N, Thornton A, Cruickshank M, et al. Factors associated with psychological distress following colposcopy among women with low-grade abnormal cervical cytology: a prospective study within the Trial Of Management of Borderline and Other Low-grade Abnormal smears (TOMBOLA). Psycho-oncology. 2013;22(2):368-80.

276.Hellsten C, Sjostrom K, Lindqvist PG. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. BJOG : an international journal of obstetrics and gynaecology. 2008;115(2):212-8.

277.Monsonego J, Cortes J, da Silva DP, Jorge AF, Klein P. Psychological impact, support and information needs for women with an abnormal Pap smear: comparative results of a questionnaire in three European countries. BMC women's health. 2011;11:18.

278.Korfage IJ, van Ballegooijen M, Wauben B, Looman CW, Habbema JD, Essink-Bot ML. Having a Pap smear, quality of life before and after cervical screening: a questionnaire study. BJOG : an international journal of obstetrics and gynaecology. 2012;119(8):936-44.

279.Hendry M, Pasterfield D, Lewis R, Clements A, Damery S, Neal RD, et al. Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing. British journal of cancer. 2012;107(2):243-54.

280.Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(4):743-8.

281.Rubin MM, Tripsas CK. Perceived uncertainty, coping strategies, and adaptation in women with human papillomavirus on pap smear. Journal of lower genital tract disease. 2010;14(2):81-9.

282.Burger EA, Nygard M, Gyrd-Hansen D, Moger TA, Kristiansen IS. Does the primary screening test influence women's anxiety and intention to screen for cervical cancer? A randomized survey of Norwegian women. BMC public health. 2014;14:360.

283.Johnson CY, Sharp L, Cotton SC, Harris CA, Gray NM, Little J, et al. Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status. PloS one. 2011;6(6):e21046.

284.Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta obstetricia et gynecologica Scandinavica. 2011;90(5):445-51.

285.Lin H, Jeng CJ, Wang LR. Psychological responses of women infected with cervical human papillomavirus: a qualitative study in Taiwan. Taiwanese journal of obstetrics & gynecology. 2011;50(2):154-8.

286.Maissi E, Marteau TM, Hankins M, Moss S, Legood R, Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. Bmj. 2004;328(7451):1293.

287.McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG : an international journal of obstetrics and gynaecology. 2004;111(12):1437-43.

288.McCaffery KJ, Irwig L, Turner R, Chan SF, Macaskill P, Lewicka M, et al. Psychosocial outcomes of three triage methods for the management of borderline abnormal cervical smears: an open randomised trial. Bmj. 2010;340:b4491.

289.Waller J, Marlow LA, Wardle J. The association between knowledge of HPV and feelings of stigma, shame and anxiety. Sexually transmitted infections. 2007;83(2):155-9.

290.Waller J, Marlow LA, Wardle J. Anticipated shame and worry following an abnormal Pap test result: the impact of information about HPV. Prev Med. 2009;48(5):415-9.

291.Waller J, McCaffery K, Kitchener H, Nazroo J, Wardle J. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. Psycho-oncology. 2007;16(3):196-204.

292.Dunn TS, Killoran K, Wolf D. Complications of outpatient LLETZ procedures. J Reprod Med. 2004;49(2):76-8.

293.Houlard S, Perrotin F, Fourquet F, Marret H, Lansac J, Body G. Risk factors for cervical stenosis after laser cone biopsy. European journal of obstetrics, gynecology, and reproductive biology. 2002;104(2):144-7.

294.Manley KM, Draycott T. Uncertainty remains about early pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Evidence-based medicine. 2015;20(2):72.

295.Wuntakal R, Castanon A, Landy R, Sasieni P. How many preterm births in England are due to excision of the cervical transformation zone? Nested case control study. BMC pregnancy and childbirth. 2015;15:232.

296.Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. Bmj. 2008;337:a1343.

297.Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Bmj. 2008;337:a1284.

298.Liu Y, Qiu HF, Tang Y, Chen J, Lv J. Pregnancy outcome after the treatment of loop electrosurgical excision procedure or cold-knife conization for cervical intraepithelial neoplasia. Gynecologic and obstetric investigation. 2014;77(4):240-4.

299.Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. Bmj. 2012;345:e5174.

300.Guo HJ, Guo RX, Liu YL. Effects of loop electrosurgical excision procedure or cold knife conization on pregnancy outcomes. European journal of gynaecological oncology. 2013;34(1):79-82.

301.Frega A, Sesti F, De Sanctis L, Pacchiarotti A, Votano S, Biamonti A, et al. Pregnancy outcome after loop electrosurgical excision procedure for cervical intraepithelial neoplasia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2013;122(2):145-9.

302.Werner CL, Lo JY, Heffernan T, Griffith WF, McIntire DD, Leveno KJ. Loop electrosurgical excision procedure and risk of preterm birth. Obstetrics and gynecology. 2010;115(3):605-8.

303.Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. European journal of obstetrics, gynecology, and reproductive biology. 2012;162(1):16-20.

304.Jakobsson M, Gissler M, Paavonen J, Tapper AM. Loop electrosurgical excision procedure and the risk for preterm birth. Obstetrics and gynecology. 2009;114(3):504-10.

305.Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH. Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. BJOG : an international journal of obstetrics and gynaecology. 2012;119(6):692-8.

306.Pils S, Eppel W, Seemann R, Natter C, Ott J. Sequential cervical length screening in pregnancies after loop excision of the transformation zone conisation: a retrospective analysis. BJOG : an international journal of obstetrics and gynaecology. 2014;121(4):457-62.

307.Castanon A, Landy R, Brocklehurst P, Evans H, Peebles D, Singh N, et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. Bmj. 2014;349:g6223.

308.Conner SN, Cahill AG, Tuuli MG, Stamilio DM, Odibo AO, Roehl KA, et al. Interval from loop electrosurgical excision procedure to pregnancy and pregnancy outcomes. Obstetrics and gynecology. 2013;122(6):1154-9.

309.Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG : an international journal of obstetrics and gynaecology. 2011;118(9):1031-41.

310.Andia D, Mozo de Rosales F, Villasante A, Rivero B, Diez J, Perez C. Pregnancy outcome in patients treated with cervical conization for cervical intraepithelial neoplasia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2011;112(3):225-8.

311.Reilly R, Paranjothy S, Beer H, Brooks CJ, Fielder HM, Lyons RA. Birth outcomes following treatment for precancerous changes to the cervix: a population-based record linkage study. BJOG : an international journal of obstetrics and gynaecology. 2012;119(2):236-44.

312.Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG : an international journal of obstetrics and gynaecology. 2010;117(3):258-67.

313.Mödrahälsovård, Sexuell och reproduktiv hälsa ARG-rapport 59 SFOG 2008.